Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

Multiple sleep difficulties common in people with early Parkinson’s

Most people with early-stage Parkinson’s disease have sleep disturbances, with many having more than one at the same time, a study in France suggests. Sleep disorders were mainly associated with body changes, including motor symptoms and problems regulating involuntary bodily functions, rather than depression or anxiety. “The timely…

Home care agency named Parkinson’s community care partner

Angels on Call, a home care services provider, has been recognized as a Community Partner in Parkinson’s Care by the Parkinson’s Foundation. The Community Partner in Parkinson’s Care membership program educates and trains staff to deliver care plans specifically focused on Parkinson’s patient’s symptoms and…

Funding secured for environmental toxins project in Parkinson’s

A researcher at the University of Wollongong in Australia has received funding of nearly 400,000 Australian dollars (about $250,000) to investigate the links between environmental toxins, such as pesticides and nanoplastics, and Parkinson’s disease. The funding, from The Michael J. Fox Foundation for Parkinson’s Research and the…

Blood test may predict dementia risk in people with REM sleep disorder

Among people with rapid eye movement (REM) sleep behavior disorder, blood biomarkers associated with dementia may help identify those at risk of developing Dementia with Lewy Bodies (DLB), a condition that shares symptoms with Parkinson’s disease. Particularly, blood levels of two proteins — amyloid-beta 42/40 ratio and p-tau…

First patient dosed in Parkinson’s clinical trial of Ventus’ VENT-02

A Phase 2a clinical trial testing Ventus Therapeutics’ VENT-02 — a novel brain-penetrating oral medication — in adults with mild to moderate Parkinson’s disease has dosed its first patient. The study (NCT06822517), expected to enroll about 30 people with Parkinson’s, is assessing the treatment’s safety, tolerability, effects on…

FDA lists platform using rhythm to aid walking as Class II device

Note: This story was updated March 13, 2025, to correct that the company’s proprietary software is not available as a downloadable smartphone app. The U.S. Food and Drug Administration (FDA) has listed MR-005, MedRhythms’ digital therapeutic platform using rhythmic beats to help with walking in…

StrivePD Guardian launched to better personalized Parkinson’s care

Rune Labs has launched StrivePD Guardian, a personalized care delivery service to help Parkinson’s disease patients manage their condition more effectively by combining expert coaching with artificial intelligence (AI)-driven health monitoring. The program pairs the StrivePD mobile app with an Apple watch, offering users continuous monitoring of…

Onward Medical using 2 grants to test spinal stimulation device

Onward Medical has received two grants totaling about $2.5 million to support early feasibility studies assessing whether its implantable spinal stimulation system, called ARC-IM, can lessen mobility difficulties and blood pressure instability in people with Parkinson’s disease. The ARC-IM system — in which targeted stimulation can…

Trial volunteer awards go to Parkinson’s, Alzheimer’s patients

A research advocate diagnosed with Parkinson’s disease and a former nurse with Alzheimer’s disease were among recipients of volunteer awards from the Global Alzheimer’s Platform Foundation (GAP). GAP’s Citizen Scientist Awards acknowledge the contributions of volunteers in clinical trials for neurodegenerative diseases. Each year, GAP’s network of research…